期刊文献+

洛匹那韦合成工艺研究 被引量:5

Synthesis of lopinavir
下载PDF
导出
摘要 目的洛匹那韦合成工艺的优选。方法以(2S,3S,5S)-2-胺基-3-羟基-5-(叔丁氧羰基胺基)-1,6-二苯基己烷的丁二酸盐为原料,经酰胺化、氨基脱保护、酰胺化三步反应制备洛匹那韦。结果较高收率合成了高纯度的洛匹那韦(纯度>99%;总产率70%)。结论得到了简洁、绿色、适于工业化生产的洛匹那韦制备工艺。 Abstrast :Objective To optimize the synthesis of lopinavir. Methods Lopinavir was synthesized via three steps including amidation, deprotection of amine, and amidation from ( 2 S, 3 S, 5 S ) -2 -amino-3 -hydroxy-5 - ( tert-butoxycarbonyl- amino ) - 1,6 -diphenyl hexane sue cinate. Results Lopinavir was synthesized with high yield and purity ( purity 〉 99% : overall yield 70% ). Conclusions A simple, green, suitable preparation process for industrial production of lopinavir was got.
出处 《安徽医药》 CAS 2014年第4期610-613,共4页 Anhui Medical and Pharmaceutical Journal
关键词 洛匹那韦 工艺优化 HIV蛋白酶抑制剂 opinavir process optimization HIV-I protease inhibitor
  • 相关文献

参考文献8

  • 1翟洪,顾振龙,柏俊,程杰.依非韦伦的合成工艺研究[J].安徽医药,2012,16(5):595-597. 被引量:4
  • 2姜辉,李俊,胡成穆.艾滋病治疗策略的研究进展[J].安徽医药,2006,10(11):803-805. 被引量:1
  • 3Reddy GK,Ali A,Nalam MN,et al.Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres[J].J Med Chem,2007,50 (18):4316-4328.
  • 4DeGoey DA,Grampovnik DJ,Flosi WJ,et al.Water-soluble prodrugs of the HIV protease inhibitors Lopinavir and Ritonavir[J].J Med Chem,2009,52(9):2964-2970.
  • 5Stoner EJ,Cooper A J,Dickman DA,et al.Synthesis of HIV protease inhibitor lopinavir[J].Organic Process Research & Development,2000,4 (1):264-269.
  • 6Chemburkar SR,Bauer J,Deming K,et al.Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development[J].Organic Process Research & Development,2000,4 (2):413-417.
  • 7Bose P,Biswas S,Rathore RS.A process for the synthesis of 2-amino-5-protected amino-3-hydroxy-1,6-diphenylhexant or a salt thereof-an intermediate of antiviral drugs[P].WO2006/090264,2006-08-31.
  • 8Stoner EJ,Stengel PJ,Cooper AJ.Synthesis of ABT-378,an HIV protease inhibitor candidate:avoiding the use of carbodiimides in a difficult peptide coupling[J].Organic Process Research & Development,1999,3 (1):145-148.

二级参考文献35

  • 1侯化,金由辛.Ribozyme在基因治疗中的研究进展[J].医学信息(医学与计算机应用),2000,13(5):265-267. 被引量:3
  • 2Corbett JW, Ko SS, Rodgers JD, et al. Inhibition of clinically rele- vant mutant variants of HIV-1 by quinazolinone non-nucleoside re- verse transcriptase inhibitors[ J]. J Med Chem ,2000,43 (10) :2019 -30.
  • 3Echeverria P, Negredo E, Carosib G, et al. Similar antiviral effica- cy and tolerability between efavirenz and lopinavir/ritonavir, admin- istered with abacavir/lamivudine (Kivexa) , in antiretroviral-naive patients : A 48-week, multicentre, randomized study [ J ]. Antiviral Research ,2010,85 (2) :403 - 8.
  • 4Thompson AS, Corley EG, Huntington MF, et al. Use of an ephed- rine alkoxide to mediate enantioselective addition of an acetylide to a prochiral ketone:asymmetric synthesis of the reverse transcfiptase inhibitor L-743,726[ J]. Terrflhpdron Letters, 1995,36(49) :8937 --40.
  • 5Radescaa LA, Loa YS, Moorea JR, et al. Synthesis of HIV-1 Reverse Transcriptase Inhibitor DMP 266 [ J ]. Synthetic Communications, 1997,27 (24) :4373 - 84.
  • 6Jiang B, Feng Y. Enantioselective alkynylafion of a prochiral ketone catalyzed by C2-symmetric diaminodiols [ J ]. Tetrahedron Lett, 2002,43 (16) :2975 - 7.
  • 7Chinkov N, Warm A, Carreira EM. Asymmetric Autocatalysis Ena- bles an Improved Synthesis of Efavirenz [ J ]. Angew Chem Int Ed, 2011,50(13) : 2957 -61.
  • 8Anusuya C, Moore JR, Pierce ME, et al. In situ recycling of chiral ligand and surplus nucleophile for a noneatalytic reaction : amplifi- cation of process throughput in the asymmetric addition step of efa- virenz (DMP 266)[J]. Organic Process Research & Development, 2003,7 (3) :324 - 8.
  • 9Tillyer RD, Chen C, Pierce ME, et al. Practical Asymmetrie synthe- sis of efavirenz ( DMP 266) ,an HIV-I reverse transeriptase inhibitor [ J ]. J Org Chem, 1998,63 (23) : 8536 - 43.
  • 10Singh GP, Mahjan P,Salunke G ,et al. An improved process for prep- aration efavircnz [ P]. W02011007367A1. 2011 - 1 - 20.

共引文献3

同被引文献46

  • 1孙平华,唐文生,张虎山,孙铁民.依巴斯汀的合成工艺改进[J].中国医药工业杂志,2004,35(6):326-327. 被引量:7
  • 2王钝,吴秀静,宫平.盐酸阿比朵尔的合成[J].中国医药工业杂志,2004,35(8):457-458. 被引量:19
  • 3马臻,王尊元,沈正荣.吡非尼酮的合成[J].中国医药工业杂志,2006,37(6):372-373. 被引量:8
  • 4周后元.合成药物生产工艺研究[J].中国医药工业杂志,1997,28(2):59-64. 被引量:14
  • 5靳立人,许志杰,蒋洪平.一种合成利托那韦的方法:中国,1247554[P].2004.12.15
  • 6Josbi A, Vron J/J, Unge J, et al. Design and synthesis of P1 P3 macrocyelic tertiary-alcohol-comprising HIV-1 protease inhlbi- torsi J]. J Med Chem,2013,56(22) : 8999 -9007.
  • 7Katende-Kyenda NL, Lubbe MS, Serfontein JHP,et al. Determining potential drug-drug interactions between lopinavir/ritonavir and other antiretrovirals and prescribed daily doses in a section of the private health care sector in South Africa[ J]. Afr J Pha Pharma- col,2013,7(41 ) : 2727 -2733.
  • 8Aspiroz EL, Cabrera Figueroa SE, Cruz R, et al. Toxicogenetics of lopinavir/ritonavir in HIV-infected European patients J ]. Person- alized Medicine ,2014, l 1 ( 3 ) :263 - 272.
  • 9Bellani P, Frigerio M, Castoldi P. Process for the synthesis of ritonavir: US,6407252B1 [ p]. 2002 -06 - 18.
  • 10Bose P, Biswas S, Rathore RS. A process for the synthesis of 2-a- mino-5-protected amino-3-hydroxy-1,6-diphenylhexant or a salt thereof-an intermediate of antiviral drugs : WO, 2006/090 264 [P].2006 -08 -31.

引证文献5

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部